IRIS
SALVATORELLI, EMANUELA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 4.251
NA - Nord America 1.272
EU - Europa 595
SA - Sud America 161
AF - Africa 28
OC - Oceania 12
Continente sconosciuto - Info sul continente non disponibili 1
Totale 6.320
Salva come PNG Salva come JPEG
Nazione #
SG - Singapore 3.128
US - Stati Uniti d'America 1.213
CN - Cina 561
HK - Hong Kong 356
IT - Italia 221
BR - Brasile 113
GB - Regno Unito 93
DE - Germania 77
FR - Francia 76
VN - Vietnam 58
CZ - Repubblica Ceca 34
IN - India 29
MX - Messico 25
BD - Bangladesh 21
CA - Canada 19
FI - Finlandia 17
NL - Olanda 16
ID - Indonesia 15
AR - Argentina 13
AU - Australia 11
CO - Colombia 10
JP - Giappone 10
UA - Ucraina 10
ZA - Sudafrica 10
PK - Pakistan 9
SA - Arabia Saudita 9
PL - Polonia 8
PH - Filippine 7
PY - Paraguay 7
BE - Belgio 6
CL - Cile 6
JO - Giordania 6
TR - Turchia 6
TW - Taiwan 6
ES - Italia 5
MY - Malesia 5
PT - Portogallo 5
RU - Federazione Russa 5
CR - Costa Rica 4
EC - Ecuador 4
IQ - Iraq 4
JM - Giamaica 4
NP - Nepal 4
AE - Emirati Arabi Uniti 3
AL - Albania 3
DO - Repubblica Dominicana 3
GE - Georgia 3
IE - Irlanda 3
LT - Lituania 3
PE - Perù 3
SE - Svezia 3
UZ - Uzbekistan 3
VE - Venezuela 3
AO - Angola 2
AT - Austria 2
BO - Bolivia 2
EE - Estonia 2
EG - Egitto 2
MA - Marocco 2
SN - Senegal 2
TN - Tunisia 2
BG - Bulgaria 1
BH - Bahrain 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
CV - Capo Verde 1
DK - Danimarca 1
DM - Dominica 1
ET - Etiopia 1
GA - Gabon 1
IL - Israele 1
KH - Cambogia 1
KN - Saint Kitts e Nevis 1
KZ - Kazakistan 1
LK - Sri Lanka 1
LV - Lettonia 1
ME - Montenegro 1
MR - Mauritania 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
OM - Oman 1
PA - Panama 1
RO - Romania 1
RW - Ruanda 1
SO - Somalia 1
SY - Repubblica araba siriana 1
TT - Trinidad e Tobago 1
XK - ???statistics.table.value.countryCode.XK??? 1
YE - Yemen 1
Totale 6.320
Salva come PNG Salva come JPEG
Città #
San Jose 462
Hong Kong 354
Singapore 341
Ashburn 244
Rome 196
Beijing 168
Hefei 162
Boardman 93
London 72
Lauterbourg 65
Dallas 63
Shanghai 52
Munich 38
Los Angeles 29
Council Bluffs 26
Brno 23
San Francisco 23
Santa Clara 23
Redmond 21
Ho Chi Minh City 18
São Paulo 16
Amsterdam 15
Pune 15
Hanoi 14
Mexico City 13
Guangzhou 12
Seattle 12
New York 11
Olomouc 10
Turku 10
Manchester 9
Tokyo 9
Toronto 9
Boston 8
Haiphong 8
Washington 8
Brooklyn 7
Nuremberg 7
Helsinki 6
Rio de Janeiro 6
Warsaw 6
Amman 5
Campinas 5
Chicago 5
Frankfurt am Main 5
Melbourne 5
Orem 5
Riyadh 5
Atlanta 4
Biên Hòa 4
Chennai 4
Dhaka 4
Hangzhou 4
Johannesburg 4
Kuala Lumpur 4
Medellín 4
Paris 4
San José 4
Shenzhen 4
Taipei 4
Ankara 3
Brasília 3
Canberra 3
Dublin 3
Haikou 3
Karachi 3
Milan 3
Mol 3
Montreal 3
New Delhi 3
Stockholm 3
Sydney 3
Tashkent 3
Tbilisi 3
The Dalles 3
Tirana 3
Wuhan 3
Asunción 2
Augusta 2
Aversa 2
Berlin 2
Buenos Aires 2
Cairo 2
Caracas 2
Changsha 2
Colombo 2
Concord 2
Curitiba 2
Dakar 2
Florence 2
Genoa 2
Guarujá 2
Hanover 2
Hasselt 2
Iowa City 2
Jakarta 2
Kingston 2
Lahore 2
Lima 2
Limeira 2
Totale 2.864
Salva come PNG Salva come JPEG
Nome #
Cardiovascular safety of anti-TNF-alpha therapies: Facts and unsettled issues. 220
Anthracyclines and Cardiotoxicity: Is CARP a Forgotten Biomarker? 206
Cancer drugs and QT prolongation: weighing risk against benefit 202
Pharmacology of Ranolazine versus Common Cardiovascular Drugs in Patients with Early Diastolic Dysfunction Induced by Anthracyclines or Nonanthracycline Chemotherapeutics: A Phase 2b Minitrial 202
Minimal sampling colistin pharmacokinetics in critically ill patients 201
Doxorubicinolone formation and efflux : A salvage pathway against epirubicin accumulation in human heart 200
Choosing Antifungals for the Midostaurin-Treated Patient: Does CYP3A4 Outweigh Recommendations? A Brief Insight from Real Life 199
The endogenous lusitropic and chronotropic agent, B-type natriuretic peptide, limits cardiac troponin release in cancer patients with an early impairment of myocardial relaxation induced by anthracyclines 194
Cardiovascular toxicity of antitumor drugs :Translating molecular mechanisms into clinical facts 191
4’- Epidoxorubicin to reexplore anthracycline degradation in cardiomyocytes 188
Anthracycline cardiotoxicity in breast cancer patients: Synergism with trastuzumab and taxanes 177
Defective taxane stimulation of epirubicinol formation in the human heart: Insights into the cardiac tolerability of epirubicin-taxane chemotherapies 177
Chronic cardiotoxicity of anticancer anthracyclines in the rat: role of secondary metabolites and reduced toxicity by a novel anthracycline with impaired metabolite formation and reactivity 156
Beyond hypertension: Diastolic dysfunction associated with cancer treatment in the era of cardio-oncology 151
Pharmacology of cardio-oncology: chronotropic and lusitropic effects of B-type natriuretic peptide in cancer patients with early diastolic dysfunction induced by anthracycline or nonanthracycline chemotherapy 136
Anthracycline Cardiotoxicity 133
Anthracyclines 124
Anthracycline degradation in cardiomyocytes: a journey to oxidative survival 120
Anthracycline Cardiotoxicity 109
Defective one or two electron reduction of the anticancer anthracycline epirubicin in human heart: Relative importance of vesicular sequestration and impaired efficiency of electron addition 100
Cardiotoxicity of antitumor drugs 99
CARDIAC ANTHRACYCLINE ACCUMULATION AND B-TYPE NATRIURETIC PEPTIDE TO DEFINE RISK AND PREDICTORS OF CANCER TREATMENT RELATED EARLY DIASTOLIC DYSFUNCTION 97
Cardiotoxicity of targeted cancer drugs: concerns, “The cart before the horse,” and lessons from trastuzumab 88
Low dose anthracycline and risk of heart failure in a pharmacokinetic model of human myocardium exposure: analog specificity and role of secondary alcohol metabolites 84
Advances in Bruton tyrosine kinase (Btk) inhibition are steered by Bruton tyrosine kinase phylogeny 82
Anthracyclines: molecular advances and pharmacological developments in antitumor activity and cardiotoxicity 75
Anthracyclines, diastolic dysfunction and the road to heart failure in Cancer survivors: An untold story 74
Isavuconazole: case report and pharmacokinetic considerations 67
Rethinking drugs from chemistry to therapeutic opportunities: Pixantrone beyond Anthracyclines. 64
Pharmacology of Cardio-Oncology 64
What is cardiotoxicity? 61
Modeling human myocardium exposure to doxorubicin defines the risk of heart failure from low-dose doxorubicin 60
Doxorubicin-Dependent Reduction of Ferrylmyoglobin and Inhibition of Lipid Peroxidation: Implications for Cardiotoxicity of Anticancer Anthracyclines 59
Further analytical, pharmacokinetic, and clinical observations on low-dose ponatinib in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia 58
Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model II. Amrubicin shows metabolic advantages over doxorubicin and epirubicin 58
Paclitaxel and docetaxel stimulation of doxorubicinol formation in the human heart: Implications for cardiotoxicity of doxorubicin-taxane chemotherapies 57
From Cardiac Anthracycline Accumulation to Real-Life Risk for Early Diastolic Dysfunction: A Translational Approach 56
Low level tumor necrosis factor-alpha protects cardiomyocytes against high level tumor necrosis factor-alpha: brief insight into a beneficial paradox 56
NEW TARGETED DRUGS FOR ACUTE MYELOID LEUKEMIA AND ANTIFUNGALS: PHARMACOKINETIC CHALLENGES AND OPPORTUNITIES 54
Ponatinib induces a persistent molecular response and graft-versus-host disease/graft-versus-leukemia effect in a patient with Philadelphia-positive acute lymphoblastic leukemia with a T315I mutation following early relapse after allogeneic transplant 53
Predictors of early or delayed diastolic dysfunction after anthracycline-based or nonanthracycline chemotherapy: a pharmacological appraisal 51
Mechanisms and clinical course of cardiovascular toxicity of cancer treatment II. Hematology 50
The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: Insight to explain the cardiac safety of pixantrone in doxorubicin treated patients 50
Oxidative degradation of cardiotoxic anticancer anthracyclines to phthalic acids. Novel function or ferrylmyoglobin 50
Telaprevir raises the plasma/whole blood ribavirin ratio: trying to come full circle on a dangerous relationship 50
Doxorubicin irreversibly inactivates Iron Regulatory Proteins 1 and 2 in cardiomyocytes : Evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy 50
Pharmacokinetics of pegylated liposomal doxorubicin administered by intraoperative hyperthermic intraperitoneal chemotherapy to patients with advanced ovarian cancer and peritoneal carcinomatosis 49
Pharmacological Foundation of Cardio-Oncology 48
Doxorubicin metabolism to toxic species in human myocardium: stimulation by paclitaxel and docetaxel but not BMS 184476 or BMS 188797 48
The concomitant management of cancer therapy and cardiac therapy 46
Formation of toxic anthracycline secondary alcohol metabolites in human myocardium: Comparisons between doxorubicin and epirubicin and effects of paclitaxel, docetaxel, and the epothilones BMS310705 and BMS247550 45
Posaconazole and midostaurin in patients with FLT3-mutated acute myeloid leukemia: Pharmacokinetic interactions and clinical facts in a real life study 42
Doxorubicin degradation in cardiomyocytes 42
Modified colistin regimen for critically ill patients with acute renal impairment and continuous renal replacement therapy 42
Matters of the heart: The case of TNF-alpha targeting drugs 41
Impairment of myocardial contractility by anticancer anthracyclines: role of secondary alcohol metabolites and evidence of reduced toxicity by a novel disaccharide analogue 40
Tumour necrosis factor alpha (TNFα)cardiomyocyte preconditioning: clues to explain anti-TNFα agents contraindication in severe heart failure 40
In vitro modelling of the structure-activity determinants of anthracycline cardiotoxicity. 40
Ferrylmyoglobin-dependent oxidative degradation of doxorubicin: a novel pathway of anthracycline metabolism and toxicity 40
Molecular determinants of the reduced cardiotoxicity of epirubicin 40
Role of secondary alcohol metabolites in anthracycline cardiotoxicity: from hypotheses to new drugs 39
Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model I Amrubicin accumulates to a lower level than doxorubicin or epirubicin 38
Primary prevention strategies for anthracycline cardiotoxicity: a brief overview 38
Managing anthracycline-induced cardiotoxicity: beginning with the end in mind 38
The use of pegylated liposomal doxorubicin with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients undergoing cytoreductive surgery (CS) for peritoneal carcinomatosis of ovarian origin 38
Phase IB and pharmacological study of the novel taxane BMS-184476 in combination with doxorubicin 38
The reality of pixantrone in real life 37
Tumor necrosis factor alpha and cardiomyocytes: evidence for a self-protective preconditioning 37
Doxorubicin inhibits ferrylmyoglobin-dependent lipid peroxidation 37
Taxanes stimolate Doxorubicin conversion to its cardiotoxic secondary alcohol metabolite doxorubicinol: studies in human myocardium 37
Tnf-alpha induced cardioprotection: effects on reactive oxygen species (ros) and apoptosis 37
Humans and Rodents: The Case of hOAT4 and mOat5 35
Increasing doxorubicin antitumor activity through COX-2 inhibition without increasing cardiotoxicity 35
Taxanes stimulate doxorubicin conversion to its cardiotoxic secondary alcohol metabolite : Studies in human myocardium. 35
Doxorubicin dependent reduction of hypervalent ferrylmyoglobin: One more evidence against the oxidative nature of doxorubicin-induced cardiotoxicity 35
Efficacy and safety of low dose ponatinib in a case of Ph-positive acute lymphoblastic leukaemia 34
Translating molecular mechanisms into clinical facts 34
Pixantrone (PIX) Inhibition of Doxorubicinol (DOXOL) Formation in Human Myocardium: Implications for Cardiac Safety in Non-Hodgkin Lymphoma (NHL) Patients with Prior Anthracycline Treatment 32
The novel anthracycline MEN 10755 is less cardiotoxic than doxorubicin or epirubicin due to reduced formation and aconitase-reactivity its secondary alcohol metabolite 31
Do you know pixantrone? 30
Doxorubicin Cardiotoxicity and the Control of Iron Metabolism: Quinone-Dependent and Independent Mechanisms 28
Totale 6.399
Salva come PNG Salva come JPEG
Categoria #
all - tutte 40.898
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 40.898
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022186 0 4 0 0 0 0 1 73 3 0 4 101
2022/202346 1 1 1 3 2 2 10 0 2 3 20 1
2023/2024280 5 32 8 12 32 123 4 16 2 7 4 35
2024/20253.593 74 34 107 13 42 68 37 20 222 238 1.303 1.435
2025/20262.294 294 186 127 209 108 62 793 174 182 159 0 0
Totale 6.399